PPARG

(redirected from PPARgamma)

PPARG

A gene on chromosome 3p25 that encodes a member of the nuclear receptor family of ligand-activated transcription factors, which heterodimerise with the retinoic X receptor (RXR) to regulate gene expression. PPARG binds peroxisome proliferators such as hypolipidaemic drugs and fatty acids, and controls the peroxisomal beta-oxidation pathway of fatty acids. It is a key regulator of adipocyte differentiation and glucose homeostasis.

Molecular pathology
Defects in PPARG mutation are linked to type-2 insulin-resistant diabetes and hypertension, obesity, glioma type 1, and cause familial partial lipodystrophy type 3.

peroxisome proliferator-activated receptor-gamma gene

,

PPARG

A gene with an allele that increases the risk of developing type 2 diabetes mellitus. People with this allele may benefit from treatment with thiazolidinedione drugs.
References in periodicals archive ?
receives royalties from various patents related to PPARgamma, SXR, and BXR.
Vanadyl acetylacetonate upregulates PPARgamma and adiponectin expression in differentiated rat adipocytes.
Screening of medicinal plants for PPARalpha and PPARgamma activation and evaluation of their effects on glucose uptake and 3T3-L1 adipogenesis.
Homology modelling of the nuclear receptors: Human oestrogen receptorbeta (hERbeta), the human pregnane-X-receptor (PXR), the Ah receptor (AhR) and the constitutive androstane receptor (CAR) ligand binding domains from the human oestrogen receptor alpha (hERalpha) crystal structure, and the human peroxisome proliferator activated receptor alpha (PPARalpha) ligand binding domain from the human PPARgamma crystal structure.
PPARgamma and GLUT-4 expression as developmental regulators/markers for preadipocyte differentiation into an adipocyte.
Distinct stages in adipogenesis revealed by retinoid inhibition of differentiation after induction of PPARgamma.
2006) PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth.
Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.
Nevertheless, it was found that rosiglitazone and indomethacin could be replaced with 13-hydroxy-octadecadienoic acid, main component of oxidized low-density lipoproteins, during PPARgamma activation.